Use of natriuretic peptide for treating heart failure


Ontology type: sgo:Patent     


Patent Info

DATE

2015-05-05T00:00

AUTHORS

MITROVIC VESELIN , LUSS HARTMUT , FORSSMANN WOLF-GEORG , MEYER MARKUS , DOHLER KLAUS

ABSTRACT

The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/32", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3215", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "MITROVIC VESELIN", 
        "type": "Person"
      }, 
      {
        "name": "LUSS HARTMUT", 
        "type": "Person"
      }, 
      {
        "name": "FORSSMANN WOLF-GEORG", 
        "type": "Person"
      }, 
      {
        "name": "MEYER MARKUS", 
        "type": "Person"
      }, 
      {
        "name": "DOHLER KLAUS", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1016/s0009-9236(98)90181-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052818063", 
          "https://doi.org/10.1016/s0009-9236(98)90181-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00059-003-2415-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035739691", 
          "https://doi.org/10.1007/s00059-003-2415-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/309724a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019610738", 
          "https://doi.org/10.1038/309724a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01726570", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028609592", 
          "https://doi.org/10.1007/bf01726570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10741-009-9149-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031273434", 
          "https://doi.org/10.1007/s10741-009-9149-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/312656a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035186021", 
          "https://doi.org/10.1038/312656a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/310699a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051790885", 
          "https://doi.org/10.1038/310699a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-05-05T00:00", 
    "description": "

The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.

", "endDate": "2026-04-07", "id": "sg:patent.US-9023794-B2", "name": "Use of natriuretic peptide for treating heart failure", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.476212.4", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-9023794-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-11-24T21:22", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/patent/patent_30.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-9023794-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-9023794-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-9023794-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-9023794-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

70 TRIPLES      15 PREDICATES      23 URIs      9 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-9023794-B2 schema:about anzsrc-for:32
2 anzsrc-for:3215
3 schema:author Nc19cc14b204b4b348e1bc8e3d5351c10
4 schema:citation sg:pub.10.1007/bf01726570
5 sg:pub.10.1007/s00059-003-2415-x
6 sg:pub.10.1007/s10741-009-9149-7
7 sg:pub.10.1016/s0009-9236(98)90181-3
8 sg:pub.10.1038/309724a0
9 sg:pub.10.1038/310699a0
10 sg:pub.10.1038/312656a0
11 schema:datePublished 2015-05-05T00:00
12 schema:description <p id="p-0001" num="0000">The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.</p>
13 schema:endDate 2026-04-07
14 schema:name Use of natriuretic peptide for treating heart failure
15 schema:recipient grid-institutes:grid.476212.4
16 schema:sameAs https://app.dimensions.ai/details/patent/US-9023794-B2
17 schema:sdDatePublished 2022-11-24T21:22
18 schema:sdLicense https://scigraph.springernature.com/explorer/license/
19 schema:sdPublisher Ne84e2e6eafef43659abf47778cfe3c33
20 sgo:license sg:explorer/license/
21 sgo:sdDataset patents
22 rdf:type sgo:Patent
23 N03aadca18d4c4a7bb8644a49f0e6b7bb rdf:first Nd8dc10f3e8a84b0eb9c4e159ab5103e2
24 rdf:rest N8ea2803519214f1497fc21c07b41bdea
25 N182541bbc15e487bbeb3fdc48fcd2a7b rdf:first N44b7c8e4f7664fd99886e08781ce8eb1
26 rdf:rest Nd675f765c5b740059026355588c213cd
27 N44b7c8e4f7664fd99886e08781ce8eb1 schema:name MEYER MARKUS
28 rdf:type schema:Person
29 N8ea2803519214f1497fc21c07b41bdea rdf:first Nbd3e17028e5e43f0859a256fb5763d9e
30 rdf:rest N182541bbc15e487bbeb3fdc48fcd2a7b
31 Na9f58db374df4380a2ea093b70272f13 schema:name DOHLER KLAUS
32 rdf:type schema:Person
33 Nbd3e17028e5e43f0859a256fb5763d9e schema:name FORSSMANN WOLF-GEORG
34 rdf:type schema:Person
35 Nc19cc14b204b4b348e1bc8e3d5351c10 rdf:first Neecace493279465bbf315ccedd307d11
36 rdf:rest N03aadca18d4c4a7bb8644a49f0e6b7bb
37 Nd675f765c5b740059026355588c213cd rdf:first Na9f58db374df4380a2ea093b70272f13
38 rdf:rest rdf:nil
39 Nd8dc10f3e8a84b0eb9c4e159ab5103e2 schema:name LUSS HARTMUT
40 rdf:type schema:Person
41 Ne84e2e6eafef43659abf47778cfe3c33 schema:name Springer Nature - SN SciGraph project
42 rdf:type schema:Organization
43 Neecace493279465bbf315ccedd307d11 schema:name MITROVIC VESELIN
44 rdf:type schema:Person
45 anzsrc-for:32 schema:inDefinedTermSet anzsrc-for:
46 rdf:type schema:DefinedTerm
47 anzsrc-for:3215 schema:inDefinedTermSet anzsrc-for:
48 rdf:type schema:DefinedTerm
49 sg:pub.10.1007/bf01726570 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028609592
50 https://doi.org/10.1007/bf01726570
51 rdf:type schema:CreativeWork
52 sg:pub.10.1007/s00059-003-2415-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1035739691
53 https://doi.org/10.1007/s00059-003-2415-x
54 rdf:type schema:CreativeWork
55 sg:pub.10.1007/s10741-009-9149-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031273434
56 https://doi.org/10.1007/s10741-009-9149-7
57 rdf:type schema:CreativeWork
58 sg:pub.10.1016/s0009-9236(98)90181-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052818063
59 https://doi.org/10.1016/s0009-9236(98)90181-3
60 rdf:type schema:CreativeWork
61 sg:pub.10.1038/309724a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019610738
62 https://doi.org/10.1038/309724a0
63 rdf:type schema:CreativeWork
64 sg:pub.10.1038/310699a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051790885
65 https://doi.org/10.1038/310699a0
66 rdf:type schema:CreativeWork
67 sg:pub.10.1038/312656a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035186021
68 https://doi.org/10.1038/312656a0
69 rdf:type schema:CreativeWork
70 grid-institutes:grid.476212.4 schema:Organization
 




Preview window. Press ESC to close (or click here)


...